Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Apr;7(3):300-304.
doi: 10.1016/j.jaccao.2025.02.004. Epub 2025 Mar 17.

Rechallenge After Severe Immune Checkpoint Inhibitor Myocarditis: Venturing Into the Unknown

Guillaume Bailly  1 , Maxime Robert-Halabi  1 , Pierre-Adrien Vion  2 , Yves Allenbach  3 , Baptiste Abbar  4 , Marie Bretagne  1 , Joe-Elie Salem  5
Affiliations
Review

Rechallenge After Severe Immune Checkpoint Inhibitor Myocarditis: Venturing Into the Unknown

Guillaume Bailly et al. JACC CardioOncol. 2025 Apr.
No abstract available

Keywords: cardio-oncology; immune-related adverse events; immunotherapy; myocarditis; pharmacology; pharmacotherapy; rechallenge.

PubMed Disclaimer

Conflict of interest statement

Funding Support and Author Disclosures Dr Salem has served as consultant for Bristol Myers Squibb, AstraZeneca, BeiGene, Ipsen, Eisai, Banook, and Novartis; and has received grants from Bristol Myers Squibb and Novartis. Drs Salem and Allenbach hold patents related to prognostication and treatment of ICI-related toxicities. Dr Abbar has received consulting fees or honoraria from Novartis, AstraZeneca, Bristol Myers Squibb, Merck Sharpe & Dohme, Astellas, and Sanofi. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.

Figures

None
Graphical abstract
Figure 1
Figure 1
Case Report Summary: Cancer and Myotoxicity Clinical Course Evolution AV = atrioventricular; CT = computed tomography; FDG = fluorodeoxyglucose; IV = intravenous; LVEF = left ventricular ejection fraction; PET = positron emission tomography; RECIST = Response Evaluation Criteria in Solid Tumors.
See this image and copyright information in PMC

References

    1. Schneider B.J., Naidoo J., Santomasso B.D., et al. Management of Immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update. J Clin Oncol. 2021;39:4073–4126. - PubMed
    1. Thompson J.A., Schneider B.J., Brahmer J., et al. NCCN Guidelines® insights: management of immunotherapy-related toxicities, version 2.2024. J Natl Compr Canc Netw. 2024;22:582–592. - PubMed
    1. Lyon A.R., Lopez-Fernandez T., Couch L.S., et al. 2022 ESC guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS) Eur Heart J. 2022;43:4229–4361. - PubMed
    1. Salem J.E., Bretagne M., Abbar B., et al. Abatacept/ruxolitinib and screening for concomitant respiratory muscle failure to mitigate fatality of immune-checkpoint inhibitor myocarditis. Cancer Discov. 2023;13:1100–1115. - PubMed
    1. Fenioux C., Abbar B., Boussouar S., et al. Thymus alterations and susceptibility to immune checkpoint inhibitor myocarditis. Nat Med. 2023;29(12):3100–3110. - PubMed

LinkOut - more resources